Association of the prefrailty with global brain atrophy and white matter lesions among cognitively unimpaired older adults: the Nakajima study

Moeko Noguchi-Shinohara1,2, Kenjiro Ono1,2, Sohshi Yuki-Nozaki1, Kazuo Iwasa3, Masami Yokogawa4, Kiyonobu Koma1, Benjamin Thyreau6,7, Yasuko Tatewaki6,8, Yasuyuki Taki6,7,8, Mao Shibata9, Tomoyuki Ohara10, Jun Hata9, Toshiharu Ninomiya9 & Masahito Yamada1,11

Physical frailty has been associated with adverse outcomes such as dementia. However, the underlying structural brain abnormalities of physical frailty are unclear. We investigated the relationship between physical frailty and structural brain abnormalities in 670 cognitively unimpaired individuals (mean age 70.1 years). Total brain volume (TBV), hippocampal volume (HV), total white matter hypointensities volume (WMHV), and estimated total intracranial volume (eTIV) on the 3D T1-weighted images were automatically computed using FreeSurfer software. Participants were divided into two states of physical frailty (robust vs. prefrail) based on the revised Japanese version of the Cardiovascular Health Study criteria. The multivariable-adjusted mean values of the TBV-to-eTIV ratio was significantly decreased, whereas that of the WMHV-to-eTIV ratio was significantly increased in the prefrail group compared with the robust group. Slowness, one of the components of physical frailty, was significantly associated with reduced TBV-to-eTIV and HV-to-eTIV ratios, and slowness and weakness were significantly associated with an increased WMHV-to-eTIV ratio. Our results suggest that the prefrail state is significantly associated with global brain atrophy and white matter hypointensities. Furthermore, slowness was significantly associated with hippocampal atrophy.

Physical frailty was reported to be associated with an increased risk of cognitive decline and dementia1,2. Physical frailty was also associated with an increased rate of decline in global cognition and cognitive components, such as episodic memory, perceptual speed, visuospatial abilities3, and executive function4. However, the etiology or mechanisms of developing dementia in people with frailty has not been clarified.

Emerging evidence suggests that physical frailty is associated with a decrease in total brain and gray matter volumes and an increase in white matter hyperintensities on fluid-attenuated inversion recovery (FLAIR)-magnetic resonance (MR) images5,7. Additionally, weakness and slowness, which are components of physical frailty, have been associated with decreases in gray matter volume and total brain volume in older adults5,7. Further, frail individuals have been reported to have a faster rate of brain atrophy5,7. On the other hand, a decrease in gray matter volume and total brain volume was associated with increases in white matter hyperintensities5,7.

1Department of Neurology, Kanazawa University Graduate School of Medical Sciences, 13-1 Takara-machi, Kanazawa 920-8640, Japan. 2Department of Preemptive Medicine for Dementia, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan. 3Department of Health and Medical Sciences, Ishikawa Prefectural Nursing University, Kahoku, Japan. 4Division of Health Sciences, Department of Physical Therapy, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan. 5Department of Medical Sciences, Ishikawa Prefectural Nursing University, Kahoku, Japan. 6Department of Neurology, Hokuriku Brain and Neuromuscular Disease Center, National Hospital Organization Iou National Hospital, Kanazawa, Japan. 7Department of Aging Research and Geriatric Medicine, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan. 8Department of Neurology, Hokuriku Brain and Neuromuscular Disease Center, National Hospital Organization Iou National Hospital, Kanazawa, Japan. 9Department of Epidemiology and Public Health, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. 10Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. 11Kudanzaka Hospital, Tokyo, Japan. *email: m-nohara@med.kanazawa-u.ac.jp; onoken@med.kanazawa-u.ac.jp
frailty, were associated with reduced gray matter and hippocampal volumes. Therefore, physical frailty might be a prodromal stage of central nervous system vascular injury. However, individuals with physical frailty often have cognitive disorders, such as mild cognitive impairment (MCI) or dementia, and previous reports might include individuals with MCI. Furthermore, brain atrophy might be affected by cognitive disorders. Therefore, to clarify how physical frailty affects the brain structure, the relationships between physical frailty and brain imaging findings in cognitively unimpaired older adults need to be established. In this study, we investigated that white matter lesions on the 3D T1-weighted images, whereas 2D FLAIR-MR images were often used to determine white matter lesions. FLAIR-MR images are more sensitive for the white matter lesions than T1-weighted images, however 3D T1-weighted images may be able to detect smaller lesions than 2D FLAIR-MR images. This study aimed to examine the relationships between physical frailty and brain structure, as measured by global brain and hippocampal volumes and white matter hypointensities on 3D T1-weighted MR images among cognitively unimpaired older adults.

Results

Characteristics of participants. Compared with the individuals excluded from our analysis (n = 1784), enrolled individuals (n = 670) had significantly lower mean values for age, median values for Geriatric Depression Scale (GDS), and the proportions for hypertension, diabetes mellitus, and depressive symptoms. Conversely, the enrolled group had significantly higher mean values for serum high-density lipoprotein (HDL) cholesterol levels and for the proportions for educational level and drinking habits (Fig. 1 and Supplementary Table 1).

Of the 670 individuals, 10 were in the frail group (1.4%), whereas 241 were in the prefrail group (35.9%) (Table 1). The prevalence rates of each determinant component of the frailty phenotype, including weight loss, slowness, weakness, exhaustion, and low physical activity, were 9.7%, 8.9%, 8.8%, 2.1%, and 14.5%, respectively (Table 1). The clinical characteristics of the study population are summarized according to the physical frailty status in Table 1. The mean values for age, the median values for GDS, and the proportions of having diabetes mellitus, depressive symptoms, and smoking habits were significantly higher, whereas the mean values for serum HDL cholesterol level and the proportions for education level were significantly lower in the prefrail and frail group than in the robust group (Table 1). There were few individuals with frail group, then we mainly compared clinical characteristics and brain volumes between the individuals with prefrail and robust group.

Regarding the components of the frailty phenotype, similar findings were obtained for individuals with slowness (Table 2), except for the proportion for hypertension and serum low-density lipoprotein (LDL) cholesterol level. Individuals with weakness were significantly older, had higher GDS scores, and had lower education levels, drinking habits, and Mini-Mental State Examination (MMSE) score (Table 2). Individuals having exhaustion had a significantly higher proportion of the depressive symptoms and GDS scores. Individuals with low physical activity were significantly younger and had higher GDS scores than those in the robust group (Table 2). When we restricted the analysis to the participants having only one component of each physical frailty, individuals with slowness were significantly higher in age, proportion of diabetes mellitus, serum LDL cholesterol levels, and GDS scores. Individuals with weakness were significantly higher in age and had significantly lower education levels, drinking habits, and MMSE score than those in the robust group (Supplementary Table 2).
### Table 1. Participant characteristics by physical frailty status.

| Variables                        | Total       | Robust      | Prefrail    | Frail      |
|----------------------------------|-------------|-------------|-------------|------------|
| N (%)                            | 670 (100)   | 419 (62.5)  | 241 (36.0)  | 10 (1.5)   |
| Age (y), mean (SD)               | 70.1 (6.4)  | 69.4 (5.7)  | 71.0 (7.3)* | 78.4 (5.7)*|
| Women (%)                        | 57.3        | 58.9        | 54.4        | 60.0       |
| Hypertension (%)                 | 72.7        | 70.2        | 75.9        | 100*       |
| Diabetes mellitus (%)            | 16.2        | 13.6        | 19.9*       | 33.3*      |
| Serum LDL-chol, mean (SD)        | 115.3 (30.2) | 116.2 (30.2) | 113.6 (30.4) | 118.9 (26.7) |
| Serum HDL-chol, mean (SD)        | 61.2 (15.3) | 62.2 (15.4) | 59.3 (15.1)* | 66.5 (15.6)* |
| Education ≤ 9 y (%)              | 35.5        | 30.5        | 43.2*       | 70.0*      |
| Smoking habit (%)                | 10.6        | 8.4         | 14.5*       | 10.0*      |
| Drinking habit (%)               | 43.5        | 46.1        | 39.0        | 40.0       |
| ApoE E4, present (%)             | 22.7        | 22.2        | 22.4        | 30.0       |
| MMSE, median (IQR)               | 29.0 (27.0–30.0) | 29.0 (27.0–30.0) | 29.0 (27.0–30.0) | 28.5 (25.0–29.2) |
| Depressive symptoms (%)          | 15.5        | 11.5        | 22.4*       | 20.0*      |
| GDS, median (IQR)                | 2.0 (1.0–4.0) | 2.0 (1.0–4.0) | 3.0 (1.0–5.0)* | 4.0 (3.7–5.5)* |
| Frailty component                |             |             |             |            |
| Weight loss, present (%)         | 9.7         | 0           | 26.6        | 40.0       |
| Slowness, present (%)            | 8.9         | 0           | 24.5        | 90.0       |
| Weakness, present (%)            | 8.8         | 0           | 24.1        | 90.0       |
| Exhaustion, present (%)          | 2.1         | 0           | 5.8         | 30.0       |
| Low physical activity (%)        | 14.5        | 0           | 39.8        | 70.0       |

Table 2. Participant characteristics in individuals with each component of the physical frailty status among 241 individuals in the prefrail group. SD standard deviation, LDL-chol low-density lipoprotein cholesterol, HDL-chol high-density lipoprotein cholesterol, MMSE Mini-mental state examination, IQR interquartile range, GDS geriatric depression scale. *p < 0.05, prefrail and frail group versus the robust group.

| Variables                        | Weight loss | Slowness | Weakness | Exhaustion | Low physical activity |
|----------------------------------|-------------|----------|----------|------------|-----------------------|
| n                                | 64          | 59       | 58       | 14         | 96                    |
| Age (y), mean (SD)               | 70.0 (65.0–75.0) | 78.0 (71.0–82.0)* | 73.0 (69.0–81.0)* | 68.5 (64.7–73.7) | 66.0 (63.0–70.0)*      |
| Women (%)                        | 48.4        | 48.5     | 62.1     | 50.0       | 57.3                  |
| Hypertension (%)                 | 77.8        | 88.1*    | 80.7     | 78.9       | 70.8                  |
| Diabetes mellitus (%)            | 21.0        | 30.5*    | 19.3     | 21.4       | 14.9                  |
| Serum LDL-chol, mean (SD)        | 112.5 (96.0–134.2) | 102.0 (85.0–123.0)* | 108.0 (90.0–133.0) | 112.5 (86.5–149.7) | 122.0 (101.0–139.2)    |
| Serum HDL-chol, mean (SD)        | 56.0 (49.7–68.2) | 55.0 (49.0–67.0)* | 56.0 (50.0–70.0) | 55.0 (51.2–60.5) | 59.5 (50.0–68.0)       |
| Education ≤ 9 y (%)              | 38.1        | 49.1*    | 56.1*    | 50.0       | 36.5                  |
| Smoking habit (%)                | 14.1        | 20.3*    | 6.9      | 21.4       | 21.4                  |
| Drinking habit (%)               | 45.3        | 37.3     | 22.4*    | 64.3       | 40.6                  |
| ApoE E4, present (%)             | 22.2        | 18.6     | 20.0     | 28.6       | 22.3                  |
| MMSE, median (IQR)               | 29.0 (27.0–30.0) | 28.0 (27.0–29.0) | 28.0 (26.0–29.0)* | 27.5 (26.0–29.0) | 29.0 (27.0–30.0)       |
| Depressive symptoms (%)          | 17.2        | 37.3*    | 20.7     | 42.9*      | 19.8                  |
| GDS, median (IQR)                | 3.0 (1.25–5.0)* | 4.0 (2.0–6.0)* | 3.5 (1.0–5.0)* | 4.5 (2.0–9.0)* | 3.0 (1.0–5.0)*         |
| Frailty component                |             |          |          |            |                       |
| Weight loss, present (%)         | –           | 10.2     | 6.9      | 0          | 6.3                   |
| Slowness, present (%)            | 9.4         | –        | 27.6*    | 21.4       | 4.2                   |
| Weakness, present (%)            | 6.3         | 27.1*    | –        | 7.1        | 9.4                   |
| Exhaustion, present (%)          | 0           | 5.1      | 1.7      | –          | 1.0                   |
| Low physical activity (%)        | 9.4         | 6.8      | 15.5     | 7.1        | –                     |

Scientific Reports | (2022) 12:12129 | https://doi.org/10.1038/s41598-022-16190-7

natureportfolio
Among ApoE E4 non-carriers, we found significant associations between prefrailty status and TBV-to-eTIV and WMHV-to-eTIV ratios, and a positive but insignificant association between slowness and HV-to-eTIV ratio (Supplementary Table 4). Additionally, significant associations were observed between weakness and WMHV-to-eTIV ratio and significantly higher mean values for the WMHV-to-eTIV ratio compared with the robust group (Table 4). When we conducted the analysis between the individuals with prefrail and frail group and robust group after adjustment for age, sex, hypertension, diabetes mellitus, LDL and HDL cholesterol levels, ApoE E4 carrier status, and MMSE score, * Benjamini–Hochberg false discovery rate-adjusted p value, q < 0.05.

### Table 3. Association of brain volume with prefrailty and its components. Values are shown as a mean value (95% confidence interval). In the multivariable-adjusted model, the values were adjusted for age, sex, educational level, hypertension, diabetes mellitus, LDL and HDL cholesterol levels, ApoE E4 carrier status, MMSE score, and GDS score.

| Physical frailty status | Age- and sex-adjusted | Multivariable-adjusted | Age- and sex-adjusted | Multivariable-adjusted | Age- and sex-adjusted | Multivariable-adjusted |
|-------------------------|-----------------------|------------------------|-----------------------|------------------------|-----------------------|------------------------|
| Robust                  | 59.1 (58.8–59.4)      | 59.0 (58.6–59.5)       | 0.48 (0.47–0.49)      | 0.48 (0.47–0.49)       | 0.29 (0.26–0.31)      | 0.29 (0.25–0.33)       |
| Prefrail                | 58.5 (58.1–58.9)      | 58.5 (58.0–59.0)       | 0.47 (0.46–0.48)      | 0.47 (0.47–0.48)       | 0.35 (0.31–0.38)      | 0.35 (0.31–0.40)       |

### Components of the physical frailty

#### Weight loss

|                           | Age- and sex-adjusted | Multivariable-adjusted | Age- and sex-adjusted | Multivariable-adjusted | Age- and sex-adjusted | Multivariable-adjusted |
|---------------------------|-----------------------|------------------------|-----------------------|------------------------|-----------------------|------------------------|
| No                        | 58.9 (58.7–59.2)      | 58.9 (58.5–59.3)       | 0.48 (0.47–0.48)      | 0.48 (0.47–0.49)       | 0.30 (0.28–0.33)      | 0.31 (0.27–0.35)       |
| Yes                       | 58.3 (57.6–59.0)      | 58.4 (57.6–59.2)       | 0.47 (0.46–0.48)      | 0.47 (0.46–0.49)       | 0.34 (0.27–0.41)      | 0.36 (0.28–0.43)       |

#### Slowness

|                           | Age- and sex-adjusted | Multivariable-adjusted | Age- and sex-adjusted | Multivariable-adjusted | Age- and sex-adjusted | Multivariable-adjusted |
|---------------------------|-----------------------|------------------------|-----------------------|------------------------|-----------------------|------------------------|
| No                        | 59.0 (58.8–59.2)      | 59.0 (58.6–59.4)       | 0.48 (0.47–0.48)      | 0.48 (0.47–0.49)       | 0.29 (0.27–0.31)      | 0.29 (0.26–0.33)       |
| Yes                       | 57.4 (56.6–58.2)      | 57.4 (56.6–58.3)       | 0.47 (0.46–0.48)      | 0.46 (0.45–0.48)       | 0.49 (0.42–0.57)      | 0.49 (0.41–0.58)       |

#### Weakness

|                           | Age- and sex-adjusted | Multivariable-adjusted | Age- and sex-adjusted | Multivariable-adjusted | Age- and sex-adjusted | Multivariable-adjusted |
|---------------------------|-----------------------|------------------------|-----------------------|------------------------|-----------------------|------------------------|
| No                        | 58.9 (58.7–59.1)      | 58.8 (58.4–59.2)       | 0.48 (0.47–0.48)      | 0.48 (0.47–0.49)       | 0.30 (0.28–0.32)      | 0.31 (0.27–0.35)       |
| Yes                       | 58.6 (57.8–59.4)      | 58.6 (57.7–59.4)       | 0.48 (0.46–0.49)      | 0.46 (0.45–0.49)       | 0.38 (0.31–0.46)      | 0.40 (0.31–0.48)       |

#### Exhaustion

|                           | Age- and sex-adjusted | Multivariable-adjusted | Age- and sex-adjusted | Multivariable-adjusted | Age- and sex-adjusted | Multivariable-adjusted |
|---------------------------|-----------------------|------------------------|-----------------------|------------------------|-----------------------|------------------------|
| No                        | 58.9 (58.6–59.1)      | 58.8 (58.4–59.2)       | 0.48 (0.47–0.48)      | 0.48 (0.47–0.49)       | 0.31 (0.28–0.33)      | 0.31 (0.28–0.35)       |
| Yes                       | 59.5 (57.9–61.0)      | 58.6 (58.0–61.2)       | 0.49 (0.46–0.52)      | 0.49 (0.46–0.52)       | 0.43 (0.28–0.58)      | 0.42 (0.27–0.57)       |

#### Low physical activity

|                           | Age- and sex-adjusted | Multivariable-adjusted | Age- and sex-adjusted | Multivariable-adjusted | Age- and sex-adjusted | Multivariable-adjusted |
|---------------------------|-----------------------|------------------------|-----------------------|------------------------|-----------------------|------------------------|
| No                        | 58.9 (58.7–59.2)      | 58.8 (58.4–59.2)       | 0.48 (0.47–0.47)      | 0.48 (0.47–0.49)       | 0.31 (0.28–0.33)      | 0.31 (0.28–0.35)       |
| Yes                       | 58.7 (58.1–59.3)      | 58.6 (57.9–59.3)       | 0.47 (0.46–0.48)      | 0.47 (0.46–0.49)       | 0.32 (0.26–0.38)      | 0.32 (0.26–0.39)       |

### Association of brain volume with physical frailty and its components.

The age- and sex-adjusted and multivariable-adjusted mean values for the total brain volume (TBV)-to-estimated total intracranial volume (eTIV), hippocampal volume (HV)-to-eTIV, and white matter hypointensities volume (WMHV)-to-eTIV ratios are presented according to frailty status in Table 3. The prefrail group had significantly lower mean values for the TBV-to-eTIV ratio and significantly higher mean values for the WMHV-to-eTIV ratio compared with the robust group after adjustment for age, sex, hypertension, diabetes mellitus, serum LDL and HDL cholesterol levels, ApoE E4 carrier status, and MMSE score. In assessing whether the five components of physical frailty were associated with each magnetic resonance imaging (MRI) parameter, the multivariable-adjusted mean values for the TBV-to-eTIV and HV-to-eTIV ratios were significantly lower, whereas those for the WMHV-to-eTIV ratios were significantly higher in individuals with slowness compared with those in the robust group (Table 3). Additionally, the multivariable-adjusted mean values for the WMHV-to-eTIV ratio were significantly higher in individuals with weakness compared with those in the robust group (Table 3). Among ApoE E4 non-carriers, we found significant associations between prefrailty status and TBV-to-eTIV and WMHV-to-eTIV ratios, and a positive but insignificant association between slowness and HV-to-eTIV ratio (Supplementary Table 4). Additionally, significant associations were observed between weakness and WMHV-to-eTIV ratio and exhaustion and WMHV-to-eTIV ratio (Supplementary Table 4). When we conducted the analysis between the individuals with prefrail and frail group and robust group, these associations remained unchanged (Supplementary Table 3).

Furthermore, we investigated whether the five components of physical frailty were associated with each MRI-extracted brain trait among individuals having only one component of each physical frailty (Table 4). Individuals with slowness had significantly lower multivariable-adjusted mean values for the TBV-to-eTIV and HV-to-eTIV ratios and higher values for the WMHV-to-eTIV ratio than those in the robust group (Table 4).

### Discussion

Our study demonstrated for the first time that the prefrail state and the components of physical frailty, such as slowness and weakness, were significantly associated with brain structural changes in cognitively unimpaired older adults. The prefrail state was significantly associated with global brain atrophy and white matter hypointensities on 3D T1-weighted imaging. Slowness was associated with global brain atrophy, reduced hippocampal volumes, and white matter hypointensities, whereas weakness was associated with white matter hypointensities. When we analyzed the participants among ApoE E4 non-carriers, we found a significant association between prefrail state and global brain atrophy and white matter hypointensities, and a positive but insignificant association was observed between slowness and reduced hippocampal volumes. This study found that the prefrail state, which is early-stage physical frailty, is associated with brain structural changes in cognitively unimpaired older adults.
| Any one component of physical frailty | Robust | 59.2 (59.0–59.5) | 59.0 (58.6–59.4) | 0.48 (0.48–0.49) | 0.48 (0.47–0.49) | 0.28 (0.26–0.30) | 0.29 (0.25–0.32) |
|--------------------------------------|--------|----------------|----------------|----------------|----------------|----------------|----------------|
| Components of physical frailty       |        |                |                |                |                |                |                |
| Weight loss                          | No     | 59.1 (58.8–59.3) | 58.9 (58.5–59.2) | 0.48 (0.48–0.48) | 0.48 (0.47–0.49) | 0.29 (0.27–0.31) | 0.30 (0.26–0.33) |
|                                      | Yes    | 58.8 (58.1–59.6) | 58.9 (58.1–59.7) | 0.48 (0.46–0.49) | 0.48 (0.47–0.50) | 0.27 (0.20–0.33) | 0.28 (0.21–0.36) |
| Slowness                             | No     | 59.1 (58.9–59.3) | 59.0 (58.6–59.3) | 0.48 (0.48–0.49) | 0.48 (0.47–0.49) | 0.29 (0.26–0.30) | 0.28 (0.25–0.31) |
|                                      | Yes    | 57.9 (56.9–58.8) | 57.9 (56.9–58.8) | 0.45 (0.44–0.47) | 0.46 (0.44–0.48) | 0.46 (0.38–0.54) | 0.46 (0.37–0.54) |
| Weakness                             | No     | 59.1 (58.9–59.3) | 58.9 (58.6–59.3) | 0.48 (0.47–0.48) | 0.48 (0.47–0.49) | 0.29 (0.27–0.30) | 0.30 (0.26–0.33) |
|                                      | Yes    | 58.7 (57.7–59.6) | 58.5 (57.4–59.6) | 0.48 (0.46–0.50) | 0.48 (0.46–0.51) | 0.28 (0.20–0.37) | 0.29 (0.20–0.39) |
| Exhaustion                           | No     | 59.0 (58.8–59.2) | 58.9 (58.5–59.2) | 0.48 (0.47–0.48) | 0.48 (0.47–0.49) | 0.29 (0.27–0.30) | 0.29 (0.26–0.33) |
|                                      | Yes    | 60.3 (58.5–62.0) | 60.3 (58.5–62.0) | 0.50 (0.46–0.53) | 0.50 (0.47–0.53) | 0.32 (0.17–0.47) | 0.31 (0.16–0.46) |
| Low physical activity                | No     | 59.1 (58.9–59.3) | 58.9 (58.6–59.3) | 0.48 (0.48–0.48) | 0.48 (0.47–0.49) | 0.29 (0.27–0.31) | 0.30 (0.27–0.33) |
|                                      | Yes    | 58.7 (58.1–59.3) | 58.3 (57.9–59.2) | 0.48 (0.46–0.49) | 0.48 (0.46–0.49) | 0.27 (0.22–0.32) | 0.27 (0.22–0.33) |
| *Benjamini–Hochberg false discovery rate-adjusted p value, q < 0.05. |

**Table 4.** Association of Brain Volume with Physical Frailty and its Components among individuals with any one component of the physical frailty status. Values were shown as a mean value (95% confidence interval). In the multivariable-adjusted model, the values were adjusted for age, sex, educational levels, hypertension, diabetes mellitus, LDL and HDL cholesterol levels, ApoE E4 carrier status, MMSE score, and GDS score.

Our analysis revealed that slowness was significantly associated with hippocampal atrophy. Individuals with slowness but no other components of frailty had significantly lower hippocampal volumes than those in the robust group. The longitudinal or cross-sectional association of hippocampal atrophy with gait speed decline has also been reported and agrees with our present findings. A randomized controlled trial showed that aerobic exercise training increases the size of the hippocampus, leading to improvements in spatial memory. Furthermore, gait speed and cognitive impairment may be partly due to a shared underlying neuropathology, and hippocampal atrophy appears to be associated with both. In rodents, it was reported that exercise enhances learning, which is accompanied by increased cell proliferation and survival in the hippocampus by increased production and secretion of brain-derived neurotrophic factor (BDNF). Also in human, exercise training increased hippocampal volume which was associated with greater serum levels of BDNF. Gait slowness related to inactivity may cause hippocampal atrophy by decreased level of BDNF. Further longitudinal studies are needed to clarify the mechanisms in the development of hippocampal atrophy and slowness prior to the onset of cognitive decline. Although frailty is thought to be a reversible state, its pathophysiology has not been fully understood. The hippocampal neurons could be easily affected by changes in synaptic and mitochondrial functions. Increasing physical activity may have long-term positive effects on hippocampal volume. The potential reversibility of physical frailty and hippocampal atrophy could be clarified in future investigations.

White matter hypointensities on 3D T1-weighted imaging are a marker of cerebral small vessel disease and may be associated with an increased risk of vascular dementia. This study found for the first time that the frailty state and especially the component of slowness were associated with white matter hypointensities. These associations remained unchanged in the analysis among the participants with ApoE4 non-carriers. Conflicting results have been reported regarding the association between physical frailty and white matter hypointensities on 3D T1-weighted imaging and white matter hyperintensities on FLAIR scans. Some studies have shown a significant association between physical frailty and white matter hyperintensities, which matches our present findings. In contrast, some studies found no association between physical frailty and white matter hyperintensities. These conflicting results may be related to a difference in the assessment criteria for physical frailty. Three previous studies used the physical frailty phenotype, one used the Frailty Index, and another one used the Edmonton Frail Scale. Further large-scale longitudinal studies are needed to clarify the association between physical frailty and white matter hypointensities on 3D T1-weighted imaging.

The limitations of this study should be addressed. First, as the findings of this study were derived from cross-sectional data, establishing a causal association between physical frailty and structural brain abnormalities was difficult. Second, we could not perform the analyses for the frail group because of the small sample size of participants classified as frail.

The study findings showed that the prefrail state was significantly associated with global brain atrophy and cerebral small vessel disease in cognitively unimpaired general older adults. Additionally, physical frailty, as determined by a multivariable-adjusted model, was associated with global brain atrophy and white matter hyperintensities, which matches previous studies. Further longitudinal studies are needed to clarify the mechanisms in the development of hippocampal atrophy and slowness prior to the onset of cognitive decline.
indicated by slowness, was significantly associated with hippocampal atrophy and cerebral small vessel disease. Further prospective longitudinal studies and basic research are required to verify the findings of this study.

### Methods

**Study population.** The Nakajima study is an ongoing population-based longitudinal cohort study that investigates cognitive decline in older Japanese individuals. The study was conducted in Nakajima, in Nanao City of Ishikawa Prefecture, Japan. The study design has been described previously. From 2016 to 2018, a total of 2454 residents aged 60 years or older (92.9% of the total population in this age group) participated in the screening examination for dementia. To clarify whether frailty is a risk factor for cognitive impairment among cognitively unimpaired older adults, we excluded patients with dementia (n = 364) and MCI (n = 427). MCI and dementia were confirmed using the clinical criteria defined by Petersen et al. and the Third Diagnostic and Statistical Manual of Mental Disorders, Revised Edition (DSM-III-R). We also excluded individuals who had hemorrhagic and/or ischemic stroke lesions on MRI regardless of the presence or absence of neurological symptoms (n = 59), no brain MRI (n = 632), or no physical frailty assessments (n = 302) (Fig. 1). Hemorrhagic and/or ischemic stroke lesions were pointed from two trained neuro-radiologists who were blinded to the clinical information. Individuals with terrible hypertension (blood pressure levels ≥ 180/110 mmHg) and individuals with leg pain during gait were excluded from physical frailty assessments.

Finally, 670 individuals were enrolled for analysis (286 male, 384 female; age, mean [standard deviation, SD] is 70.1 [6.4] years).

**Standard protocol approvals and participant consent.** This study was conducted in accordance with the guidelines of the Declaration of Helsinki and all procedures were approved by the Medical Ethics Review Board of Kanazawa University (Approval Number 2185). We obtained written informed consent from all participants.

**MRI analysis.** The structural MRI studies were performed using a 1.5 T system (ECHELON RX; Hitachi, Japan). A 3D volumetric acquisition of a T1-weighted turbo field echo images was conducted according to the brain MRI protocol for the Alzheimer’s Disease Neuroimaging Initiative (ADNI) study (Echo time/Repetition time; 4.0/9.2 ms; flip angle, 8°; Field of View, 240 mm; acquisition matrix, 192 × 192; number of slices, 170; voxel size, 0.9375 × 0.9375 mm; slice thickness, 1.2 mm). All T1-structural images were analyzed using FreeSurfer version 5.3 (FreeSurfer version 5.3; [http://surfer.nmr.mgh.harvard.edu](http://surfer.nmr.mgh.harvard.edu)) in Tohoku University and preprocessed according to the standard manner. The volumes of the area of interest were created by FreeSurfer, and the HV and WMHV were calculated as the sum of the volumes of the right and left hippocampi and white matter hypointensities, respectively. TBV was calculated by summing the white and gray matter volumes and eTIV was used to normalize each volumetric value. In this study, we evaluated three parameters, namely, the TBV-to-eTIV ratio (%), HV-to-eTIV ratio (%), and WMHV-to-eTIV ratio (%), to determine the potential indices of global brain atrophy, hippocampal atrophy, and severity of cerebral small vessel disease, respectively.

**Assessment of physical frailty.** This study assessed physical frailty and its phenotype according to the Fried criteria, namely, weight loss, slowness, weakness, exhaustion, and low physical activity. We collected data from 2016 to 2018 and assessed physical frailty using the revised Japanese version of the Cardiovascular Health Study criteria (revised J-CHS criteria), except for exhaustion.

Weight loss was assessed by responses to the self-reported question “Have you (unintentionally) lost 2 kg or more in the past 6 months?” (“Yes” = 1 point). Slowness was defined as a comfortable gait speed < 1.0 m/s (1 point). Weakness was defined as a maximum grip strength < 28 kg in men and < 18 kg in women (1 point). Exhaustion was assessed by responses to the self-reported questions “Did you feel that everything you did was an effort?” and “Did you feel exhausted without any reason?” (“Yes” to either = 1 point) using the operational definition of exhaustion in the Sasaguri Genkimon Study. Low physical activity was assessed by responses to the self-reported questions “Do you do low levels of physical exercise?” and “Do you do moderate levels of physical exercise or sports?” (“No” to both = 1 point). Based on these definitions, we defined the frail group as having 3 points or more, the prefrail group as having 1 or 2 points, and the robust group as 0 point. Since only 10 people were in the frail group, we analyzed the frail group together with the prefrail group.

**Other risk factor measurements.** Each participant completed a self-administered questionnaire that contains questions on sociodemographic data (age, sex, and educational level), medical history (diabetes mellitus and hypertension), drug information, smoking, and drinking habits. The completed questionnaires were reviewed by researchers trained to identify inconsistent or unanswered items. Depressive symptoms were evaluated using the GDS–Short Form, and a GDS score of ≥ 6 was used to denote depressive symptoms. Blood pressure was measured three times using a sphygmomanometer, with an interval of at least 5 min. The average of the three measurements was used for further analysis. Hypertension was determined by blood pressure levels ≥ 140/90 mmHg or the current use of antihypertensive agents. Body mass index (BMI, kg/m²) was measured as an indicator of obesity. Serum high-density lipoprotein (HDL) and low-density lipoprotein (LDL) cholesterol levels were enzymatically measured. The ApoE phenotype was determined using isoelectric electrophoresis as described by Kamboh et al.

**Statistical analyses.** Clinical characteristics of each frailty status were compared using the t-test for the mean values of continuous variables, the Mann–Whitney U test for median values for the MMSE and GDS, and
the chi-squared test for continuous and categorical variables. A two-tailed $p < 0.05$ was considered statistically significant. Analysis of covariance was used to estimate and compare the age- and sex-adjusted or multivariable-adjusted values and their 95% confidence intervals for the TBV-to-eTIV, HV-to-eTIV, and WMHV-to-eTIV ratios. In the multivariable-adjusted analysis, age, sex, educational level, hypertension, diabetes mellitus status, LDL, and HDL cholesterol levels, ApoE E4 carrier status, MMSE score, and GDS score were analyzed as covariates. The problem of multiple comparisons was solved by controlling the Benjamini–Hochberg false discovery rate (FDR). The FDR-adjusted $p$ values (i.e., $q$ values) below 0.05 were considered statistically significant. The SPSS software package (version 26; SPSS Inc., Chicago, IL, USA) was used to perform all statistical analyses.

Data availability
The datasets used in the current study are not publicly available, because they contain confidential clinical data on the study participants. However, the data are available on reasonable request and with the permission of the corresponding author, Moeko Noguchi-Shinohara (Department of Neurology and Neurobiography of Aging, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan).

Received: 10 January 2022; Accepted: 6 July 2022
Published online: 01 August 2022

References
1. Sofrizzri, V. et al. Frailty syndrome and the risk of vascular dementia: the Italian longitudinal study on aging. Alzheimers Dement 9, 113–122. https://doi.org/10.1016/j.jalz.2011.09.223 (2013).
2. Clegg, A., Young, J., Iliffe, S., Rikkert, M. O. & Rockwood, K. Frailty in elderly people. Lancet 381, 752–762. https://doi.org/10.1016/S0140-6736(12)62167-9 (2013).
3. Boyle, P. A., Buchman, A. S., Wilson, R. S., Leurgans, S. E. & Bennett, D. A. Physical frailty is associated with incident mild cognitive impairment in community-based older persons. J. Am. Geriatr. Soc. 58, 248–255. https://doi.org/10.1111/j.1532-5415.2009.02671.x (2010).
4. Gross, A. L. et al. Declines and impairment in executive function predict onset of physical frailty. J. Gerontol. Biol. Sci. Med. Sci. 71, 1624–1630. https://doi.org/10.1093/gerona/gow067 (2016).
5. Avila-Funes, J. A. et al. Vascular cerebral damage in frail older adults: the AMImage study. J. Gerontol. Biol. Sci. Med. Sci. 72, 971–977. https://doi.org/10.1093/gerona/glw347 (2017).
6. Siejka, T. P. et al. White matter hyperintensities and the progression of frailty-the tasmanian study of cognition and gait. J. Gerontol. Biol. Sci. Med. Sci. 75, 1545–1550. https://doi.org/10.1093/gerona/glz024 (2020).
7. Kant, I. M. et al. The association between brain volume, cortical brain infarcts, and physical frailty. Neurobiol. Aging 70, 247–253. https://doi.org/10.1016/j.neurobiology.2018.06.032 (2018).
8. Nishita, Y. et al. Links between physical frailty and regional gray matter volumes in older adults: a voxel-based morphometry study. J. Am. Med. Dir. Assoc. 20, 1587–1592. https://doi.org/10.1016/j.jamda.2019.09.001 (2019).
9. Chen, W. T. et al. Reduced cerebellar gray matter is a neural signature of physical frailty. Hum. Brain Mapp. 36, 3666–3676. https://doi.org/10.1002/hbm.22870 (2015).
10. Del Brutto, O. H. et al. Neuroimaging signatures of frailty: a population-based study in community-dwelling older adults (the atahualpa project). Geriatr. Gerontol. Int. 17, 270–276. https://doi.org/10.1111/jgg.12708 (2017).
11. Chung, C. P. et al. Structural brain microbleeds are associated with physical frailty: a community-based study. Neurobiol. Aging 44, 134–150. https://doi.org/10.1016/j.neurobiology.2016.04.025 (2016).
12. Callisaya, M. L. et al. Brain structural change and gait decline: a longitudinal population-based study. J. Am. Geriatr. Soc. 61, 1074–1079. https://doi.org/10.1111/jgs.12331 (2013).
13. Lee, S., Kim, E. Y. & Shin, C. Longitudinal association between brain volume change and gait speed in a general population. Exp. Gerontol. 118, 26–30. https://doi.org/10.1016/j.exger.2019.01.004 (2019).
14. Erickson, K. I. et al. Exercise training increases size of hippocampus and improves memory. Proc. Natl. Acad. Sci. U. S. A. 108, 3017–3022. https://doi.org/10.1073/pnas.1015950108 (2011).
15. Rosso, A. L. et al. Aging, the central nervous system, and mobility. J. Gerontol. Biol. Sci. Med. Sci. 68, 1379–1386. https://doi.org/10.1093/gerona/gor089 (2013).
16. Vaynman, S., Ying, Z. & Gomez-Pinilla, F. Hippocampal BDNF mediates the efficacy of exercise on synaptic plasticity and cognition. Eur. J. Neurosci. 20, 2580–2590. https://doi.org/10.1111/j.1460-9568.2004.03720.x (2004).
17. Fried, L. P. et al. Frailty in older adults: evidence for a phenotype. J. Gerontol. Biol. Sci. Med. Sci. 56, M146–156. https://doi.org/10.1093/gerona/gor036 (2001).
18. Bishop, N. A., Lu, T. & Yankner, B. A. Neural mechanisms of ageing and cognitive decline. Nature 464, 529–535. https://doi.org/10.1038/nature08983 (2010).
19. Fraser, M. A., Walsh, E. I., Shaw, M. E., Anstey, K. J. & Cherbuin, N. Longitudinal effects of physical activity change on hippocampal volumes over up to 12 years in middle and older age community-dwelling individuals. Cereb. Cortex https://doi.org/10.1093/cercor/bhba375 (2021).
20. Wardlaw, J. M. et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 12, 822–838. https://doi.org/10.1016/S1474-4422(13)70124-8 (2013).
21. Noguchi-Shinohara, M. et al. Differences in the prevalence of dementia and mild cognitive impairment and cognitive functions between early and delayed responders in a community-based study of the elderly. J. Alzheimers Dis. 37, 691–698. https://doi.org/10.3233/JAD-130398 (2013).
22. Petersen, R. C. et al. Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence-based review) - report of the quality standards subcommittee of the American academy of neurology. Neurology 56, 1133–1142. https://doi.org/10.1212/WNL.56.9.1133 (2001).
23. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders 5th edn. (American Psychiatric Association, Washington, DC, 1987).
24. Jack, C. R. Jr. et al. Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology 55, 484–489. https://doi.org/10.1212/01.wnl.55.4.484 (2000).
25. Fischl, B. et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron 33, 341–355. https://doi.org/10.1016/0896-6273(02)00569-x (2001).
26. Desikan, R. S. et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage 31, 968–980. https://doi.org/10.1016/j.neuroimage.2006.01.021 (2006).
27. Satake, S. & Araji, H. The revised Japanese version of the cardiovascular health study criteria (revised J–CHS criteria). Geriatr. Gerontol. Int. 20, 992–993. https://doi.org/10.1111/jgg.14005 (2020).
28. Chen, S. et al. Screening for frailty phenotype with objectively-measured physical activity in a west Japanese suburban community: evidence from the Sasaguri Genkimon Study. BMC Geriatr. 15, 36. https://doi.org/10.1186/s12877-015-0037-9 (2015).
29. Sheik, I. I. & Yesavage, J. A. Geriatric Depression Scale (GDS): Recent Evidence and Development of a Shorter Version 165–173 (Hawthorn Press, Stroud, 1986).
30. Ninomiya, T. et al. Study design and baseline characteristics of a population-based prospective cohort study of dementia in Japan: the Japan prospective studies collaboration for aging and dementia (JPSC-AD). Environ. Health Prev. Med. 25, 64. https://doi.org/10.1186/s12199-020-00903-3 (2020).
31. Kamboh, M. I., Ferrell, R. & Kottke, B. Genetic studies of human apolipoproteins V: a novel rapid procedure to screen apolipoprotein E polymorohism. J. Lipid Res. 29, 1535–1543 (1998).
32. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate - a practical and powerful approach to multiple testing. J. R. Stat. Soc. B 57, 289–300. https://doi.org/10.1111/j.2517-6161.1995.tb02031.x (1995).

Acknowledgements
We wish to thank all residents of Nakajima town for their participation in this study.

Author contributions
M.N.S., study concept and design, acquisition of data, analysis of data, interpretation of data, and writing original draft; KO, critical revision of the manuscript and supervision; S.Y.N. and K.K., acquisition of data and writing review; K.I. and M.Y., acquisition of data, interpretation of data and writing review; B.T., Y.T., and Y.T., analysis of data and critical revision of the manuscript; M.S., T.O., J.H., and T.N., critical revision of the manuscript; M.Y., study concept and design and critical revision of the manuscript.

Funding
This study was supported by JSPS KAKENHI (JP17KO9795), the Japan Agency for Medical Research and Development (dk0207025) and Suntory Holdings Limited (Osaka, Japan). The sponsor had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript.

Competing interest
Toshiharu Ninomiya received funds from the Japan Agency for Medical Research and Development and Suntory Holdings Limited (Osaka, Japan). Other authors assert that they have no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-022-16190-7.

Correspondence and requests for materials should be addressed to M.N.-S. or K.O.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022